MYCN and neuroblastoma: In a pan-cancer study, pazopanib was unable to affect the viability of the any of the treated cell lines, which included SK-N-BE(2) (N-Myc amplified) and SH-SY5Y (non-N-Myc amplified) NB cell lines, the KHOS OS cell line, and the RMS cell lines RH30 and RD.